GENOMCORE S.L., also known for its line of personalized health services under the MADE OF GENES brand, has received funding for the largest funded artificial  intelligence project to personalize the treatment of metastatic cancer. The project is funded by the European Union within the Next Generation EU program, which will cover approximately 7.5 million euros of the consortium's overall budget (10,692,931 euros), of which GENOMCORE will receive 919,610.22 euros  from the funds which accounts for 80% of the total budget.

The DIPCAN project (digitization and comprehensive management of personalized medicine) seeks to change the way these cancers are treated in Spain, thanks to the integration of clinical, genomic, anatomopathological data and radiological imaging of more than 2000 patients, using techniques of artificial intelligence. According to Oscar Flores, CEO of GENOMCORE, “We are experiencing the digital transformation of the healthcare industry into data-driven medicine of unprecedented complexity. From GENOMCORE we are proud to have positioned ourselves as a reference partner in the management of personal bio-health data for the implementation of personalized medicine by hospitals, research centres and the pharmaceutical industry with projects as disruptive as DIPCAN.”

The results could change the clinical practice in oncology by betting on the effective implementation of personalized medicine in healthcare settings, achieving the simulation and critical improvement of the subject under study. The project will last two years and will have, in addition to GENOMCORE, the participation of leading companies in the sector such as MD Anderson Spain Foundation, Eurofins Megalab, Artelnics, Pangaea Oncology, Quibim and Atrys Health.